Go Pro
TSE:BHC

Bausch Health Companies Q3 2024 Earnings Report

Bausch Health Companies logo
C$8.74 -0.29 (-3.21%)
As of 04:19 PM Eastern

Bausch Health Companies EPS Results

Actual EPS
C$1.53
Consensus EPS
C$1.43
Beat/Miss
Beat by +C$0.10
One Year Ago EPS
N/A

Bausch Health Companies Revenue Results

Actual Revenue
$3.42 billion
Expected Revenue
$3.36 billion
Beat/Miss
Beat by +$63.06 million
YoY Revenue Growth
N/A

Bausch Health Companies Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bausch Health Companies Earnings Headlines

Zacks Research Has Bearish Outlook for TSE:BHC Q3 Earnings
Brokers Set Expectations for TSE:BHC FY2026 Earnings
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Bausch Health (BHC) Q2 2026 Earnings Call Transcript
See More Bausch Health Companies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch Health Companies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch Health Companies and other key companies, straight to your email.

About Bausch Health Companies

Bausch Health Companies (TSE:BHC) (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

View Bausch Health Companies Profile